Low‐dose IL‐2 treatment: Activation of discrete T‐ and NK‐cell sub‐populations in vivo

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

1987 • 64,270 citations

Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction

1987 • 45,673 citations

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

1982 • 2,228 citations

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

1994 • 1,108 citations

Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients

1989 • 1,003 citations

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

1993 • 986 citations

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

1994 • 934 citations

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.

1994 • 921 citations

Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity

1981 • 703 citations

The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments.

1993 • 664 citations

Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors.

1990 • 436 citations

An experimentally validated panel of subfamily‐specific oligonucleotide primers (V_α1‐w29/V_β1‐w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction

1992 • 302 citations

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

1985 • 293 citations

Oligoclonality of tumor-infiltrating lymphocytes from human melanomas.

1994 • 232 citations

LOW-DOSE INTERLEUKIN-2 INDUCES SYSTEMIC IMMUNE RESPONSES AGAINST HBsAg IN IMMUNODEFICIENT NON-RESPONDERS TO HEPATITIS B VACCINATION

1989 • 174 citations

Direct evidence to support the immunosurveillance concept in a human regressive melanoma.

1994 • 171 citations

Lowest dose interleukin-2 immunotherapy [see comments]

1993 • 141 citations

Inpatient continuous-infusion interleukin-2 in 788 patients with cancer the national biotherapy study group experience

1993 • 134 citations

T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions.

1994 • 114 citations

Lowest dose interleukin-2 immunotherapy [see comments]

1993 • 110 citations

The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2.

1989 • 107 citations

Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.

1991 • 101 citations

Heterogeneity of subcellular localization of p53 protein in human glioblastomas.

1994 • 90 citations

Dominant determinants in hen eggwhite lysozyme correspond to the cryptic determinants within its self-homologue, mouse lysozyme: implications in shaping of the T cell repertoire and autoimmunity.

1993 • 84 citations

In vivo T-cell clonal amplification at time of acute graft-versus-host disease

1994 • 82 citations

Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection.

1993 • 82 citations

Evidence for T-cell clonal expansion in a patient with squamous cell carcinoma of the head and neck.

1994 • 56 citations

In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma.

1995 • 53 citations

Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study

1993 • 30 citations

Cutaneous response to recombinant interleukin 2 in human immunodeficiency virus 1-seropositive individuals.

1990 • 21 citations